Wanshou Cui1, Huixi Li1, Ruili Guan1, Meng Li1, Bicheng Yang1, Zhanwei Xu2, Maofan Lin2, Long Tian3, Xiaodong Zhang3, Bao Li4, Weiguang Liu4, Zhilong Dong5, Zhiping Wang5, Tao Zheng6, Weixing Zhang6, Guiting Lin7, Yinglu Guo1, Zhongcheng Xin1. 1. Andrology Center, Peking University First Hospital, Beijing 100034, China. 2. Wanbeili Medical instrument Co., Ltd., Beijing 102200, China. 3. Department of Urology, Beijing Chaoyang Hospital, Beijing 100020, China. 4. Department of Urology, Affiliated Hospital of Weifang Medical University, Weifang 261031, China. 5. Department of Urology, Lanzhou University Second Hospital, Lanzhou 730030, China. 6. Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. 7. Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.
Abstract
BACKGROUND: In our previous study, a novel low-intensity pulsed ultrasound (LIPUS) therapeutic device has been shown to improve erectile function non-invasively in a diabetic-induced erectile dysfunction (ED) animal model. METHODS: In order to investigate the efficacy and safety of LIPUS in the clinical treatment of patients with ED, a multicenter, randomized, double-blind, sham-treated, controlled clinical study was conducted at five medical centers, and 120 patients with mild to moderate ED were enrolled in the study. Patients were randomized into a sham-treated control group (40 patients) or a LIPUS-treated group (80 patients). LIPUS or sham treatment was applied to both sides of the penis shaft and crus for 5 min in each area, twice a week for four weeks. Assessment of efficacy and safety were evaluated using IIEF-5, Sexual Encounter Profile (SEP)-questionnaires 2/3, Global Assessment Question (GAQ), Erectile Hardness Score (EHS), Erection Quality Scale (EQS) score, and pain assessment [Visual Analogue Scale/Score (VAS)]. RESULTS: Ten patients in LIPUS treatment group and 6 patients in sham treatment control group were excluded and the dropout rate is 13.33%. Response to treatment was identified as IIEF-5 score increased more than 2/3/4 points of post-treatment (12W) compared to pre-treatment (0W). The response rate in treatment group was 54/80 (67.50%), which was significantly higher than control group 8/40 (20.00%) at 12 weeks (FAS analysis). The percentage of patients with positive answers to SEP-3 (successful vaginal intercourse) were 58.97%, 64.1%, and 73.08% 4, 8, and 12 weeks after treatment which were significantly higher than 28.95%, 31.58%, and 28.95% respectively in control group (FAS, P<0.05). The positive responsive rates for GAQ in treatment group were about 2 to 3 times of that in control group (P<0.05). No treatment-related adverse events (AEs) were found, including local petechia or ecchymosis and hematuria. CONCLUSIONS: Current study indicates that LIPUS can safely and effectively treat patients with mild to moderate ED without significant AEs, which is related to the mechanical force of LIPUS and can restore the pathological changes of the corpus cavernosum. LIPUS is a promising alternative treatment for ED treatment in the near future, while further research is remanded.
BACKGROUND: In our previous study, a novel low-intensity pulsed ultrasound (LIPUS) therapeutic device has been shown to improve erectile function non-invasively in a diabetic-induced erectile dysfunction (ED) animal model. METHODS: In order to investigate the efficacy and safety of LIPUS in the clinical treatment of patients with ED, a multicenter, randomized, double-blind, sham-treated, controlled clinical study was conducted at five medical centers, and 120 patients with mild to moderate ED were enrolled in the study. Patients were randomized into a sham-treated control group (40 patients) or a LIPUS-treated group (80 patients). LIPUS or sham treatment was applied to both sides of the penis shaft and crus for 5 min in each area, twice a week for four weeks. Assessment of efficacy and safety were evaluated using IIEF-5, Sexual Encounter Profile (SEP)-questionnaires 2/3, Global Assessment Question (GAQ), Erectile Hardness Score (EHS), Erection Quality Scale (EQS) score, and pain assessment [Visual Analogue Scale/Score (VAS)]. RESULTS: Ten patients in LIPUS treatment group and 6 patients in sham treatment control group were excluded and the dropout rate is 13.33%. Response to treatment was identified as IIEF-5 score increased more than 2/3/4 points of post-treatment (12W) compared to pre-treatment (0W). The response rate in treatment group was 54/80 (67.50%), which was significantly higher than control group 8/40 (20.00%) at 12 weeks (FAS analysis). The percentage of patients with positive answers to SEP-3 (successful vaginal intercourse) were 58.97%, 64.1%, and 73.08% 4, 8, and 12 weeks after treatment which were significantly higher than 28.95%, 31.58%, and 28.95% respectively in control group (FAS, P<0.05). The positive responsive rates for GAQ in treatment group were about 2 to 3 times of that in control group (P<0.05). No treatment-related adverse events (AEs) were found, including local petechia or ecchymosis and hematuria. CONCLUSIONS: Current study indicates that LIPUS can safely and effectively treat patients with mild to moderate ED without significant AEs, which is related to the mechanical force of LIPUS and can restore the pathological changes of the corpus cavernosum. LIPUS is a promising alternative treatment for ED treatment in the near future, while further research is remanded.
Authors: H Ikai; T Tamura; T Watanabe; M Itou; A Sugaya; S Iwabuchi; Y Mikuni-Takagaki; S Deguchi Journal: J Periodontal Res Date: 2008-04 Impact factor: 4.419
Authors: Giovanni Corona; David M Lee; Gianni Forti; Daryl B O'Connor; Mario Maggi; Terence W O'Neill; Neil Pendleton; Gyorgy Bartfai; Steven Boonen; Felipe F Casanueva; Joseph D Finn; Aleksander Giwercman; Thang S Han; Ilpo T Huhtaniemi; Krzysztof Kula; Michael E J Lean; Margus Punab; Alan J Silman; Dirk Vanderschueren; Frederick C W Wu Journal: J Sex Med Date: 2009-11-19 Impact factor: 3.802
Authors: Thomas Hausner; Krisztián Pajer; Gabriel Halat; Rudolf Hopf; Robert Schmidhammer; Heinz Redl; Antal Nógrádi Journal: Exp Neurol Date: 2012-05-01 Impact factor: 5.330
Authors: Eric Chung; Joe Lee; Chia Chu Liu; Hisanori Taniguchi; Hui Liang Zhou; Hyun Jun Park Journal: World J Mens Health Date: 2020-06-02 Impact factor: 5.400
Authors: Soyeun Kim; Min Chul Cho; Sung Yong Cho; Hong Chung; Mahadevan Raj Rajasekaran Journal: World J Mens Health Date: 2020-03-16 Impact factor: 5.400